Neurocrine Biosciences, Inc.
12790 El Camino Real
480 articles with Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers, healthcare providers and employees.
Neurocrine Biosciences, Inc. will present at the Cowen 40th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020, in Boston.
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx
Neurocrine Biosciences, Inc. announced the appointment of Shalini Sharp to its Board of Directors.
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
Neurocrine Biosciences, Inc. announced that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020.
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
Neurocrine Biosciences Owns Option to Exclusively License ACT-709478, a Clinical Stage Selective T-type Calcium Channel Blocker for the Treatment of Epilepsy
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
Neurocrine Biosciences, Inc. will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time on Monday, Jan. 13, 2020, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.
The seven featured companies are the top companies headquartered in Biotech Beach based on 2018 revenue.
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 8:30 am Eastern Time (5:30 am Pacific Time) today to provide a corporate update on the license and collaboration agreement that was announced this morning to develop first-in-class treatments for epilepsy with Neurocrine Biosciences, Inc.
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy.
The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms
Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences
Neurocrine Biosciences, Inc. announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA® and its clinical development programs..
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for Monday, November 4
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal movements in adults with tardive dyskinesia (TD), a potentially irreversible and often persistent involuntary movement disorder.
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disorder.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD); opicapone, an investigational adjunctive treatment for Parkinson's disease (PD) in the U.S.; and VY-AADC, a gene therapy for PD acquired through a strategic collaboration with Voyager Therapeutics.